Cognition Therapeutics Expands Zervimesine Access Program, Reaches Full Enrollment in Dementia with Lewy Bodies Trial

Cognition Therapeutics has reached full enrollment in its expanded access program for Zervimesine (CT1812) in dementia with Lewy Bodies (DLB). The program was made possible by a generous donation from a participant's family in the Phase 2 SHIMMER study. The Company is pursuing input from the FDA on a registrational program for DLB, with a Type C meeting scheduled for January. Zervimesine has not been approved by regulatory authorities, and its safety and efficacy have not been fully characterized.